These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29949532)

  • 21. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
    Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
    Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
    [No Abstract]   [Full Text] [Related]  

  • 22. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
    Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
    PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
    Kitanaka A; Shimoda K
    Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681
    [No Abstract]   [Full Text] [Related]  

  • 24. Essential thrombocythemia in a child: management with anagrelide.
    Chintagumpala MM; Steuber CP; Mahoney DH; Ogden AK; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1991; 13(1):52-6. PubMed ID: 2029080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary management of essential thrombocythemia in children.
    Randi ML; Bertozzi I; Putti MC
    Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
    Wong RS; Lam LW; Cheng G
    Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
    Griesshammer M
    Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
    Diep R; Metjian A
    J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
    Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
    Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
    [No Abstract]   [Full Text] [Related]  

  • 35. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
    Laguna MS; Kornblihtt LI; Marta RF; Michiels JJ; Molinas FC
    Clin Appl Thromb Hemost; 2000 Jul; 6(3):157-61. PubMed ID: 10898276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
    Yao QM; Zhou J; Gale RP; Li JL; Li LD; Li N; Chen SS; Ruan GR
    Hematology; 2015 Oct; 20(9):517-22. PubMed ID: 25860380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.